Addressing the Growing Colorectal Cancer Incidence in Younger Populations

Commentary
Video

Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.

Due to the “terrifying” rising incidence of colorectal cancer (CRC) in younger populations, it has become critical to perform screening more frequently among individuals even in their late 20s and 30s who might be at risk of developing this disease, suggested Gregory Charak, MD.

Charak, a board-certified colorectal surgeon at Palisades Medical Center and Hackensack University Medical Center of Hackensack Meridian Health, spoke with CancerNetwork® about his strategies for mitigating the rise in CRC cases among younger patients through increased screening procedures. In the event of weight changes, for instance, Charak said he and his colleagues would not hesitate to perform a colonoscopy to monitor younger at-risk individuals.

According to a news release from The American College of Surgeons, the rate of colon cancer diagnoses has increased by 15% since 2004 in patients ages 18 to 50 years old based on data derived from the National Cancer Database. Compared with this younger population, the rate of colon cancer diagnoses has increased by 3% among adults 45 to 55 years old across the same period. Factors such as environmental changes, exposure to toxins, and individual genetics are believed to have influenced this growth in diagnoses among younger populations.

Transcript:

It’s terrifying, and we don’t know what’s going on. Institutionally, or nationally, we’ve certainly taken this step of lowering the age of first screening for colorectal cancer. Now, we advise people with average risk at their first colonoscopy at 45. Personally, and certainly among my colleagues, we are much quicker to perform a colonoscopy and to go looking for something in our younger patients. If you are in your 30s, even in your late 20s, and you’re having changes in your weight or have blood in your stool, we won’t hesitate to perform a colonoscopy because we know that there’s a small possibility—but a real possibility—that there could be a cancer, and so we look.

Reference

Colorectal cancer awareness month: what to know about the rise of colorectal cancer in younger adults. News release. The American College of Surgeons. March 5, 2024. Accessed April 22, 2024. https://tinyurl.com/3ux2hnds

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Related Content